Immunohistochemical staining of SOX-10  of human FFPE tissue followed by incubation with HRP labeled secondary and development with DAB substrate.

SOX-10 [Polyclonal] Antibody (cGMP).

$ 135.00$ 605.00
Please Select Product Options Below To View The Catalog Number.

SKU: QIVD201
Species: Human
Tested Applications: IHC [IVD]
Available Conjugates:
Isotype: Rabbit Undetermined

Product NumberDescriptionPrice
QIVD201-0.1ml Size: 0.1 ml, Format: Concentrate $ 158.00
QIVD201-0.5ml Size: 0.5 ml, Format: Concentrate $ 448.00
QIVD201-1ml Size: 1 ml, Format: Concentrate $ 678.00
QIVD201-6ml Size: 6 ml, Format: Predilute $ 248.00
Shipping Information
In Stock
Flat Rate Shipping Anywhere in the US: $45
Datasheets and Documentation
Product Datasheet
Certificate of Analysis and Tags (Coming Soon)
Lot Number:

Expiration Date:

Concentration (Write Lyophilized if Lyophilized):

Reconsitution Instructions (Leave Blank if Liquid):

Manufacture Date:

Purity:

Bioactivity (test results eg. IU/ml):


SKU: QIVD201-0.1ml
SOX-10 General Information
Alternate Names
Molecular Weight
49.9 kDa
Chromosomal Location
q13.1 [chr: 22] [chr_start: 37970686] [chr_end: 37987422] [strand: -1]
Curated Database and Bioinformatic Data
Gene SymbolSOX10
Entrez Gene ID6663
RefSeq Protein Accession(s)NP_008872
RefSeq mRNA Accession(s); NM_006941
RefSeq Genomic Accession(s)NG_007948; NC_000022
UniProt ID(s)P56693
PharmGKB ID(s)PA36027
KEGG Gene ID(s)hsa:6663
Associated Diseases (KEGG IDs)Waardenburg syndrome 2E (WS2E) [MIM:611584]: An autosomal dominant auditory-pigmentary disorder characterized by sensorineural deafness, pigmentary disturbances of the hair, skin and eyes, and absence of dystopia canthorum which is the lateral displacement of the inner canthus of each eye. Individuals with WS2E may have neurologic abnormalities, including mental impairment, myelination defects, and ataxia. Some patients can manifest features of Kallmann syndrome. {ECO:0000269|PubMed:10441344, ECO:0000269|PubMed:17999358, ECO:0000269|PubMed:21898658}. The disease is caused by mutations affecting the gene represented in this entry.; Waardenburg syndrome 4C (WS4C) [MIM:613266]: A disorder characterized by the association of Waardenburg features (depigmentation and deafness) with the absence of enteric ganglia in the distal part of the intestine (Hirschsprung disease). {ECO:0000269|PubMed:18348274, ECO:0000269|PubMed:21898658, ECO:0000269|PubMed:9462749}. The disease is caused by mutations affecting the gene represented in this entry.; Peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome and Hirschsprung disease (PCWH) [MIM:609136]: A complex neurocristopathy that includes features of 4 distinct syndromes: peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome and Hirschsprung disease. {ECO:0000269|PubMed:10762540, ECO:0000269|PubMed:15004559, ECO:0000269|PubMed:19208381, ECO:0000269|PubMed:21898658}. The disease is caused by mutations affecting the gene represented in this entry.
General Description of SOX-10 .
SOX-10, a member of the sex-determining region Y-related HMG-box family, is a transcription factor that is expressed in pre-migratory and migrating neural crest cells. Following migration it remains expressed in cells destined for glial, schwannian, and melanocytic differentiation. SOX10 is widely expressed in normal human tissues including melanocytes and breast tissue. SOX10 is also an important marker in malignant tumors such as melanoma, and breast carcinomas of basal-like and triple negative type, gliomas, and benign tumors such as schwannomas. More importantly, SOX10 has been shown to be expressed in 97-100% of desmoplastic and spindle cell melanomas and has also been shown to be expressed in 100% of nevi. Spindle cell and desmoplastic melanomas are rare variants of invasive cutaneous melanoma, with an annual incidence rate of approximately 2 per 100,000. The majority of oligodendrogliomas and a large percentage of astrocytomas and poorly differentiated glioblastomas have also been shown to express SOX10.

Antibody (Suitable for clinical applications)

Sample Type: FFPE Patient Samples.
Tested Applications: IHC. Approved for In Vitro Diagnostic Procedures on FFPE tissues. For tissue collection recommendations, please see datasheet sent with product.
Application Notes
Specification Recommendation
Recommended Dilution (Conc) 1:50-1:100
Pretreatment EDTA Buffer pH 8.0
Incubation Parameters 30 min at Room Temperature

Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.

Clonality: Polyclonal
Anti-SOX-10 Antibody Clone: Polyclonal
Host and Isotype: Rabbit Undetermined
Recommended Positive Control Sample: Melanoma
Cellular Localization of Antibody Polyclonal Staining: Nuclear
Buffer and Stabilizer: PBS with 1% BSA and 0.05% NaN3
Antibody Concentration: Lot specific. Plese contact tech support for data.
Immunogen: Recombinant fragment corresponding to residues in human SOX-10 protein
Storage Conditions: This antibody should be stored refrigerated (2-8°C). This product should not be used past the expiration date printed on the vial.

SOX-10 Information for Pathologists

Summary:

SRY-related HMG-box 10 (SOX10) protein. Transcription factor known to be crucial in the specification of the neural crest and maintenance of Schwann cells and melanocytes. Expressed in nuclei of melanocytes, breast myoepithelial cells. Clinical features Usually positive nuclear staining in breast basal-like / unclassified triple negative / metaplastic carcinoma (Hum Pathol 2013;44:959).

Notable Clinical Features:

Usually positive nuclear staining in breast basal-like / unclassified triple negative / metaplastic carcinoma (Hum Pathol 2013;44:959). Usually negative / rarely positive staining in breast luminal A/B or HER2+ carcinoma (5% positive), ER-/PR- DCIS (4% positive), phyllodes tumor, fibroadenoma. Specific (93%), but not very sensitive (67%) for malignant peripheral nerve sheath tumor over synovial sarcoma (Mod Pathol 2014;27:55). Must interpret with caution in intraneural tumors. In major salivary glands, expressed in nuclei of acini and both luminal and abluminal cells of intercalated ducts, but not in other sites (Mod Pathol 2013;26:1041).

Common Uses By Pathologists:

Melanoma marker (100%, Appl Immunohistochem Mol Morphol 2014;22:142). Nevi are positive (Nat Cell Biol 2012;14:882), desmoplastic melanoma may be only focally positive (Appl Immunohistochem Mol Morphol 2013;21:506). SOX10 shows an increased specificity for soft tissue tumors of neural crest origin compared with S100 (Appl Immunohistochem Mol Morphol 2012;20:445). MITF1 and SOX10 can be used to differentiate melanoma in situ from actinic keratosis with melanocytic hyperplasia (Am J Dermatopathol 2014;36:124). Microscopic (histologic) images

Limitations and Warranty

This antibody is manufactured in accordance with clinical good manufacturing practices in an ISO13485:2016 certified production facility. It is intended for multiple uses including in vitro diagnostic use and research use only applications. Please see vial label for expiration date. We strive to always deliver antibodies with a shelf life of at least two years.

There are no reviews yet.

Be the first to review “SOX-10 [Polyclonal] Antibody (cGMP).”

Your email address will not be published. Required fields are marked *

Share a Protocol (View Reviewed Protocols Below)

Protocol Title

Materials

Methods

Notes


  protocol submission gif
enQuire Bio, LLC   8420 S Continental Divide Rd, #202   Littleton, CO 80127
Phone: 1-855-344-1400 | enquire@enquirebio.com | Fax: 1-720-897-3730
Customer Service Available M-F 8AM-6PM MST or 24/7 Via Email

SOX-10 [Polyclonal] Antibody (cGMP).